<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>Clinicians | LiquidMammo™</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta
    name="description"
    content="Information for clinicians about LiquidMammo™, a microRNA-based liquid biopsy developed to complement breast cancer screening, particularly in dense-breasted patients."
  />

  <!-- Styles -->
  assets/css/styles.css

  <!-- Favicon -->
  favicon.png
</head>

<body>

<header class="container">
  <nav>index.html← Home</a></nav>
</header>

<main class="container">

  <h1>Information for Clinicians</h1>

  <!-- Overview -->
  <section class="section-tight">
    <p>
      LiquidMammo™ is a supplemental, non‑invasive <strong>microRNA‑based liquid biopsy</strong> designed to
      strengthen breast‑cancer screening performance—especially in <strong>dense breasts</strong> where
      mammographic sensitivity is reduced.
    </p>
    <p class="notice" style="margin-top:14px;">
      LiquidMammo is currently being developed as a <strong>CLIA Laboratory Developed Test (LDT)</strong>.
      It is not yet FDA‑cleared/approved and is undergoing analytical and clinical validation.
    </p>
  </section>

  <!-- Why clinicians may use it -->
  <section class="panel-light section-tight">
    <h2>Why consider a supplemental molecular test?</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));margin-top:16px;">
      <div class="card-mini">
        <h4>Improved assessment in dense breasts</h4>
        <p class="small">
          Mammographic sensitivity may fall to ~61% in BI‑RADS D tissue. A density‑independent molecular signal
          can improve overall diagnostic confidence.
        </p>
      </div>

      <div class="card-mini">
        <h4>Non‑invasive &amp; easy to add</h4>
        <p class="small">
          A routine blood draw—no radiation, no compression, minimal patient burden.
        </p>
      </div>

      <div class="card-mini">
        <h4>Supports clinical decision‑making</h4>
        <p class="small">
          Provides complementary biological information to guide follow‑up strategies and imaging escalation
          when indicated.
        </p>
      </div>
    </div>
  </section>

  <!-- Biological rationale -->
  <section class="section-tight">
    <h2>Biological rationale</h2>
    <p>
      <span class="scientific-term">microRNAs</span> regulate gene expression across oncogenic pathways, including
      proliferation, immune modulation, and metastatic signaling. Their stability in blood and early dysregulation
      during tumor development make them promising biomarkers for screening support.
    </p>
  </section>

  <!-- How it works -->
  <section class="section-tight">
    <h2>How the test works</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));margin-top:18px;">
      <div class="card-mini">
        <h4>1 — Order through your practice</h4>
        <p class="small">
          The test is clinician‑ordered like any routine lab assay. Phlebotomy can be performed in‑clinic
          or through standard partner labs.
        </p>
      </div>

      <div class="card-mini">
        <h4>2 — Laboratory microRNA analysis</h4>
        <p class="small">
          Plasma is stabilized and processed under SOP‑driven conditions. A multi‑marker
          <span class="scientific-term">microRNA</span> signature is quantified and analyzed.
        </p>
      </div>

      <div class="card-mini">
        <h4>3 — Clinician‑ready report</h4>
        <p class="small">
          You receive a structured report including result classification, density‑contextual interpretation,
          and recommendations for appropriate follow‑up.
        </p>
      </div>
    </div>
  </section>

  <!-- Ideal use cases -->
  <section class="panel-light section-tight">
    <h2>Ideal patient populations</h2>

    <ul class="list-tight">
      <li>Women with <strong>dense breasts</strong> (BI‑RADS C or D).</li>
      <li>Patients with elevated risk or family history.</li>
      <li>Patients who defer mammography due to <strong>pain or discomfort</strong>.</li>
      <li>Younger women not yet eligible for routine mammography but with risk factors.</li>
      <li>Patients requiring <strong>more frequent monitoring</strong> between imaging intervals.</li>
    </ul>
  </section>

  <!-- Test interpretation -->
  <section class="section-tight">
    <h2>Interpreting results</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));margin-top:16px;">
      <div class="card-mini">
        <h4>Negative / Low‑risk</h4>
        <p class="small">
          Suggests no detectable signal consistent with known cancer‑associated microRNA patterns.
          Continue guideline‑directed screening.
        </p>
      </div>

      <div class="card-mini">
        <h4>Positive / Elevated signal</h4>
        <p class="small">
          Indicates presence of microRNA changes associated with tumor biology. Consider additional imaging
          (diagnostic mammography, ultrasound, or MRI) as clinically appropriate.
        </p>
      </div>
    </div>

    <p class="small" style="margin-top:10px;">
      Results should never be interpreted in isolation—clinical history, density, and imaging remain essential.
    </p>
  </section>

  <!-- Safety & quality -->
  <section class="panel-light section-tight">
    <h2>Safety, quality, and compliance</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr));margin-top:18px;">
      <div class="card-mini">
        <h4>CLIA environment</h4>
        <p class="small">
          Testing is performed in a certified CLIA laboratory following strict SOPs, QC checkpoints,
          and proficiency standards.
        </p>
      </div>

      <div class="card-mini">
        <h4>Sample integrity</h4>
        <p class="small">
          Stabilized plasma handling ensures reproducibility. Chain‑of‑custody and barcoding maintain
          sample traceability.
        </p>
      </div>

      <div class="card-mini">
        <h4>Privacy &amp; security</h4>
        <p class="small">
          All patient data are de‑identified for analysis and handled under HIPAA‑aligned workflows.
        </p>
      </div>
    </div>
  </section>

  <!-- Enrollment -->
  <section id="enroll" class="section">
    <h2>Clinician enrollment</h2>

    <p>
      We are accepting a limited number of clinical partners for early access and validation‑phase
      collaborations. Practices with diverse patient populations—including dense‑breasted and
      under‑screened groups—are encouraged to inquire.
    </p>

    <div style="margin-top:18px;display:flex;gap:12px;flex-wrap:wrap;">
      contact.html#cliniciansRequest Enrollment</a>
      patients.html#patientsPatient Information</a>
    </div>
  </section>

</main>

<footer>
  <div class="container footer-grid">
    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC, and operates out of LabCentral,
        Cambridge, MA (MIT innovation ecosystem).
      </p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end;text-align:right">
      assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">Developed by<br/>MultiOmics Inc.</div>
    </div>
  </div>

  <div class="container footer-note">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    privacy.htmlPrivacy &amp; Compliance</a> •
    contact.htmlContact</a>
  </div>
</footer>

</body>
</html>

